It looks like nothing was found at this location. Please try searching below:
It looks like nothing was found at this location. Please try searching below:
I never received, and/or I cannot find the call-in number or my link to log into the presentation?
I never received my meeting materials?
Electronic Version of the meeting material components will be available on the presentation platform, under “Resource Tab”. Or I can email them to you.
Electronic Slides are also available on the presentation platform under “Resource Tab” OR at:www.LLS.org/programs. Also, for anyone logging on through the weblink above, they can follow along during the live presentation.
For anyone saying they did not receive the print packets and do not have access to a computer, we can send them AFTER the program if they would like. Please take their information. Please note: SLIDES are not included in this packet. There are NO print version of the slides, they would just listen in via the telephone.
I am 10 minutes late, can I still call-in?
Yes
I cannot stay on for the entire call, do I just hang up when I need to leave?
Yes
Something came up and I will not be able to call-in, will I be able to listen to this at a later date?
Yes, the audio, slides and transcript will be available (not as a synced presentation) on LLS’s website at www.lls.org/programs – this will be available approximately 4 weeks after the program
I didn’t register, but can I still call-in? (Day of the program)
Yes
Is there a fee for this program?
There is no fee for this program. The Leukemia & Lymphoma Society provides free resources to patients, caregivers, and healthcare professionals.
How should I participate in this program?
If you have a computer, you can view the presentation and listen in through your computer. You can type in questions during the program and the moderator will relay questions to the speaker during the Question and Answer session.
If you do not have a computer, you can dial in using the toll-free number which will be provided once you register. There will also be an opportunity to ask a question during the Q&A session for people on the telephones.
Is the telephone number for registration the same as the telephone number for the program?
No, there will be a toll-free telephone number provided for the program after you register.
If I can’t participate on that day, can I still get the information?
Yes, you should still register. We will remind you about the program and you can get updates regarding when the audio replay is available or when a virtual lecture is available (if applicable).
We invite you to learn more about:
Healthcare professionals invited to participate.
Assistance for people with disabilities, grievances, questions, or for more information on LLS programs, please call an Information Specialist toll-free at (800) 955-4572.
Matthew S. Davids, MD, MMSc Associate Director Center for Chronic Lymphocytic Leukemia Assistant Professor of Medicine Harvard Medical School Dana Farber Institute Boston, MA |
After obtaining an A.B. in chemistry at Harvard College, Dr. Davids completed his M.D. at Yale University School of Medicine. He served as an intern, resident, and assistant chief resident in internal medicine at New York-Presbyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City. He then completed his fellowship in hematology and oncology in Dana-Farber/Partners CancerCare, and a Masters in Medical Science (MMSc) at Harvard Medical School. He is an attending physician in the Lymphoma Program of the Division of Hematologic Malignancies at Dana-Farber, an Assistant Professor in Medicine at Harvard Medical School, and is the Associate Director of the Dana-Farber CLL Center. Dr. Davids has an active translational research program in chronic lymphocytic leukemia (CLL), studying Bcl-2 biology in his laboratory and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. His work focuses on the Bcl-2 inhibitor venetoclax, novel combinations of B cell receptor pathway inhibitors, and checkpoint blockade to enhance anti-tumor immunity in patients with hematologic malignancies who relapse post allogeneic hematopoietic cell transplantation.